DUBLIN--(BUSINESS WIRE)--The "Wet Age-related Macular Degeneration - Pipeline Insights, 2017" drug pipelines has been added to ResearchAndMarkets.com's offering.
Wet Age-related Macular Degeneration - Pipeline Insights, 2017 provides comprehensive insights about pipeline drugs across this indication. This report further provides information on the therapeutic development of more than 20+ pipeline drugs at various stages covering Phase III, Phase II and Phase I and contains a comparative assessment by product type, route of administration and molecule type.
More than half of the clinical products are undergoing Phase II clinical studies and three had entered late stage (Phase III) of development. The report also provides list of 25+ (Pre-clinical and Discovery) products. Further, The report contains list of the 25+ dormant products in this space. Leading companies in this space are Novartis, OHR Pharmaceutical, Allergan and Opthotech.
Comparative analysis of pipeline drugs at various stages and their therapeutic assessment by product type and molecule type provides additional and vital details of the pipeline drugs. Information on various technologies involved in the development of pipeline therapeutics along with all the collaborations and agreements of the respective company brings added the advantage of this report. Patent and Financing details related to the products are also provided.
Key Topics Covered:
- Overview
- Age-Related Macular Degeneration
- Risk factors for AMD
- Wet AMD - Pathogenesis
- Wet AMD - Clinical Features & Diagnosis
- Wet AMD - Treatment Options
- Pipeline Therapeutics (Active Products)
- Comparative Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Abicipar: Allergan
- DE-122: Santen Pharmaceutical
- AS101: BioMAS
- Product Description
- Research and Development
- More drugs in detailed report
- Pre-clinical & Discovery Stage Products
- Therapeutic Assessment: Active Products
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
-
Assessment by Molecule Type
Companies Mentioned
- Acucela
- Adalta
- Adverum Biotechnologies
- Aerie Pharmaceuticals
- Allergan
- Benitech Biopharma
- Charlesson
- Coherus Biosciences
- Daiichi Sankyo
- GreyBug Vision
- Hemera Biosciences
- MeiraGTx
- Novartis
- Ocular Therapeutix
- OHR Pharmaceutical
- Opthotech Corporation
- Oxford Biomedica
- PanOptica
- pSivida
- Quark
- Regeneron
- Roche
- RXI Pharmaceuticals
-
SciFluor Life Sciences
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fs72ll/wet_agerelated?w=4
